Expression of the Epidermal Growth Factor Receptor in Ovarian Cancer

Abstract

Ovarian cancer is one of the most lethal neoplasms in gynecological cancers having high levels of resistance to the usual treatments.Identifying tumor targets for biological therapies responds to the need to develop new therapeutic strategies against this type of tumor. Different studies have shown that there is an association between EGF ligand expression, as well as receptors and prognosis of patients with ovarian cancer. High levels of EGFr are associated with proliferation, invasion, metastasis and resistance to chemotherapy. High levels of EGFr are associated with proliferation, invasion, metastasis and resistance to chemotherapy.The use of anti-EGF products, such as the CIMAvax-EGF vaccine, could be beneficial in the treatment of ovarian cancer, which constitutes a therapeutic option for these patients.